Heart Attack Risk in Cancer Patients by Cancer Type

This site is intended for healthcare professionals

Multiple Myeloma Shows Highest Heart Attack Risk in Cancer Patients

Author:
man having a heart attack

Key Summary:

  • Multiple myeloma had the highest myocardial infarction (MI) risk among cancer subtypes.
  • Standardized one-year MI risk remained below 1% across all 13 cancer subgroups.
  • One-year mortality varied widely, making competing mortality essential to interpreting cardiovascular risk.

HEART attack risk in cancer patients varies by subtype, with multiple myeloma showing the highest relative risk.

A nationwide Danish study of 660,531 patients found significant differences in one-year myocardial infarction (MI) risk across 13 cancer subtypes. The findings highlight the importance of considering cancer type and competing mortality when evaluating cardiovascular outcomes after a cancer diagnosis.

Heart Attack Risk Differs Across Cancer Types

Researchers analyzed registry data from adults diagnosed with cancer between 2000 and 2023. Patients with a history of MI or coronary revascularization before their cancer diagnosis were excluded. The study compared outcomes across cancer subtypes using patients with low-risk skin tumors as the reference group.

Multiple myeloma was associated with the highest relative MI risk, at 1.80 times that of the reference group (95% CI, 1.34–2.26). Elevated relative risks were also observed in bladder cancer (1.52), kidney cancer (1.51), leukemia (1.45), and gastrointestinal cancer (1.37).

Despite these differences, standardized one-year absolute MI risk remained below 1% across all cancer subtypes. Estimates ranged from 0.31% in breast cancer to 0.91% in multiple myeloma. Bladder cancer had a standardized risk of 0.86%, while kidney cancer had a risk of 0.72%.

Competing Mortality Shapes Cardiovascular Risk

One-year all-cause mortality varied substantially across cancer groups, from 2.2% among patients with low-risk skin tumors to 71.9% among those with hepatobiliary and pancreatic cancer.

The authors emphasized that this competing risk of death is important when interpreting early cardiovascular outcomes. A lower observed incidence of MI does not necessarily indicate lower underlying cardiovascular susceptibility when mortality from cancer is high.

The comparison group also requires careful interpretation: patients with low-risk skin tumors were selected as a cancer-active reference population, not as a cancer-free control group.

Implications for Cardio-Oncology

The findings describe differences in early MI risk across cancer populations but do not establish that cancer subtype itself causes those differences. The observational study also lacked consistent detailed information on cancer treatment regimens and timing, and some lifestyle-related cardiovascular risk factors were unavailable.

The authors characterize the results as hypothesis-generating. Further research may help clarify how cancer prognosis, treatment exposure, and cardiovascular risk interact.

For clinicians, the study underscores the need to interpret heart attack risk in cancer patients in the context of both cardiovascular outcomes and the competing risk of cancer-related mortality.

Reference

Shanmuganathan JWD et al. Myocardial infarction risk across cancer subtypes – a nationwide registry-based follow-up study. International Journal of Cardiology. 2027;467:135076. doi:10.1016/j.ijcard.2026.135076.

Featured Image: sebra on Adobe Stock

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.